menu
    • menu

    Company profile for Vaxess

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    We are committed to developing next-generation products that lead to better patient outcomes and are more easily distributed at home or around the world. Vaxess Technologies is a biotechnology company headquartered in Cambridge, Massachusetts. Formed in 2012 by founders from Harvard University, the company is developing its proprietary sustained release smart delivery technologies originally developed at Tufts University and M...
    We are committed to developing next-generation products that lead to better patient outcomes and are more easily distributed at home or around the world. Vaxess Technologies is a biotechnology company headquartered in Cambridge, Massachusetts. Formed in 2012 by founders from Harvard University, the company is developing its proprietary sustained release smart delivery technologies originally developed at Tufts University and MIT. Vaxess Technologies is a venture capital and Gates Foundation-backed life science company developing novel vaccine formulations and delivery technologies based on its proprietary silk platform.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    VaxessUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    c/o 790 Memorial Drive Cambridge MA, 02139
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.vaxess.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/vaxess-technologies
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/vaxess

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    AstraZeneca and Vaxess developing skin patch mRNA vaccines for pandemic flu
    AstraZeneca and Vaxess developing skin patch mRNA vaccines for pandemic flu

    23 Aug 2023

    // Ryan Cross ENDPTS

    https://endpts.com/exclusive-astrazeneca-and-vaxess-to-develop-skin-patch-mrna-vaccine-for-pandemic-flu-under-dod-grant/

    Ryan Cross ENDPTS
    23 Aug 2023
    Share Share
    Vaccine patch passes clinical test, supporting further trials
    Vaccine patch passes clinical test, supporting further trials

    20 Dec 2022

    // Nick Paul Taylor FIERCEPHARMA

    https://www.fiercepharma.com/pharma/vaxess-flu-vaccine-patch-passes-early-clinical-test-clearing-path-further-development

    Nick Paul Taylor FIERCEPHARMA
    20 Dec 2022
    Share Share
    Vaxess to Produce First GMP Batch of MIMIX Technology Vaccine Patches
    Vaxess to Produce First GMP Batch of MIMIX Technology Vaccine Patches

    05 Apr 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220405005481/en

    BUSINESSWIRE
    05 Apr 2022
    Share Share
    Vaxess Bolsters To Vaccine Patch Leadership With Purpose-Built Cambridge Lab
    Vaxess Bolsters To Vaccine Patch Leadership With Purpose-Built Cambridge Lab

    01 Mar 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220301005343/en

    BUSINESSWIRE
    01 Mar 2022
    Share Share
    Vaxess Technologies Announces Grand Opening of GMP Manufacturing Facility
    Vaxess Technologies Announces Grand Opening of GMP Manufacturing Facility

    26 Oct 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20211026005379/en

    BUSINESSWIRE
    26 Oct 2021
    Share Share
    Taiwan & US to develop coronavirus, influenza combo patch vaccine
    Taiwan & US to develop coronavirus, influenza combo patch vaccine

    15 Sep 2020

    // BIOSPECTRUM ASIA

    https://www.biospectrumasia.com/news/34/16717/standigm-partners-with-excelra-to-enhance-ai-driven-drug-discovery-process.html

    BIOSPECTRUM ASIA
    15 Sep 2020
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search